Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Update

$Sagimet Biosciences (SGMT.US)$ Reuters· 3 mins ago
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for Mash; Phase 3 Program Initiation Expected by End of 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
3480 Views
Comment
Sign in to post a comment